RecruitingPhase 1NCT06966024

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

An Open-label, Phase 1 Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer

Sponsor

Deciphera Pharmaceuticals, LLC

Enrollment

60 participants

Start Date

Aug 27, 2025

Study Type

INTERVENTIONAL

Conditions

Urothelial Carcinoma Renal Cell Carcinoma Castration-resistant Prostate Cancer

Summary

This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
Able to take oral medication
If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements
Adequate organ function and electrolytes

Exclusion Criteria3

Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812
Impaired cardiac function
Major surgery within 28 days of the first dose of study drug